LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

MannKind Corp

Suletud

SektorTervishoid

4.59 2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.5

Max

4.61

Põhinäitajad

By Trading Economics

Sissetulek

-12M

668K

Müük

-1.8M

77M

P/E

Sektori keskmine

35.455

35.724

Kasumimarginaal

0.873

Töötajad

403

EBITDA

-17M

9.7M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+105.45% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

5.2M

1.2B

Eelmine avamishind

2.59

Eelmine sulgemishind

4.59

Uudiste sentiment

By Acuity

15%

85%

22 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

MannKind Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. aug 2025, 18:43 UTC

Suurimad hinnamuutused turgudel

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29. aug 2025, 15:07 UTC

Omandamised, ülevõtmised, äriostud

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

29. aug 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

29. aug 2025, 20:24 UTC

Tulu

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29. aug 2025, 20:17 UTC

Tulu

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29. aug 2025, 19:18 UTC

Market Talk

Oil Futures End Week With Modest Gains -- Market Talk

29. aug 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29. aug 2025, 18:36 UTC

Tulu

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29. aug 2025, 18:26 UTC

Tulu

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29. aug 2025, 17:48 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29. aug 2025, 17:10 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29. aug 2025, 16:57 UTC

Tulu

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29. aug 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29. aug 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29. aug 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29. aug 2025, 16:26 UTC

Omandamised, ülevõtmised, äriostud

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29. aug 2025, 16:24 UTC

Omandamised, ülevõtmised, äriostud

BBVA Adjusts Offer for Banco de Sabadell

29. aug 2025, 16:23 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29. aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29. aug 2025, 16:06 UTC

Market Talk

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29. aug 2025, 15:12 UTC

Market Talk
Tulu

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29. aug 2025, 15:09 UTC

Tulu

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29. aug 2025, 15:01 UTC

Market Talk

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29. aug 2025, 14:49 UTC

Tulu

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29. aug 2025, 14:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29. aug 2025, 14:49 UTC

Market Talk

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29. aug 2025, 14:48 UTC

Tulu

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29. aug 2025, 14:43 UTC

Market Talk

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

29. aug 2025, 14:38 UTC

Market Talk

With Canada's Economy Soft, Central Bank Easing Looks Likely -- Market Talk

Võrdlus sarnastega

Hinnamuutus

MannKind Corp Prognoos

Hinnasiht

By TipRanks

105.45% tõus

12 kuu keskmine prognoos

Keskmine 9.43 USD  105.45%

Kõrge 12 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi MannKind Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.079 / 4.323Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

22 / 372 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.